194 related articles for article (PubMed ID: 20541046)
1. Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.
Yang M; Trettel LB; Adams DJ; Harrison JR; Canalis E; Kream BE
Bone; 2010 Sep; 47(3):573-82. PubMed ID: 20541046
[TBL] [Abstract][Full Text] [Related]
2. Effect of osteoblast-targeted expression of bcl-2 in bone: differential response in male and female mice.
Pantschenko AG; Zhang W; Nahounou M; McCarthy MB; Stover ML; Lichtler AC; Clark SH; Gronowicz GA
J Bone Miner Res; 2005 Aug; 20(8):1414-29. PubMed ID: 16007339
[TBL] [Abstract][Full Text] [Related]
3. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone.
Sher LB; Woitge HW; Adams DJ; Gronowicz GA; Krozowski Z; Harrison JR; Kream BE
Endocrinology; 2004 Feb; 145(2):922-9. PubMed ID: 14617568
[TBL] [Abstract][Full Text] [Related]
4. Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling.
Sher LB; Harrison JR; Adams DJ; Kream BE
Calcif Tissue Int; 2006 Aug; 79(2):118-25. PubMed ID: 16927049
[TBL] [Abstract][Full Text] [Related]
5. Cloning and in vitro characterization of alpha 1(I)-collagen 11 beta-hydroxysteroid dehydrogenase type 2 transgenes as models for osteoblast-selective inactivation of natural glucocorticoids.
Woitge H; Harrison J; Ivkosic A; Krozowski Z; Kream B
Endocrinology; 2001 Mar; 142(3):1341-8. PubMed ID: 11181553
[TBL] [Abstract][Full Text] [Related]
6. Col1a1 promoter-targeted expression of p20 CCAAT enhancer-binding protein beta (C/EBPbeta), a truncated C/EBPbeta isoform, causes osteopenia in transgenic mice.
Harrison JR; Huang YF; Wilson KA; Kelly PL; Adams DJ; Gronowicz GA; Clark SH
J Biol Chem; 2005 Mar; 280(9):8117-24. PubMed ID: 15598659
[TBL] [Abstract][Full Text] [Related]
7. The 3.6 kb DNA fragment from the rat Col1a1 gene promoter drives the expression of genes in both osteoblast and osteoclast lineage cells.
Boban I; Jacquin C; Prior K; Barisic-Dujmovic T; Maye P; Clark SH; Aguila HL
Bone; 2006 Dec; 39(6):1302-12. PubMed ID: 16938497
[TBL] [Abstract][Full Text] [Related]
8. Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing.
Weber AJ; Li G; Kalak R; Street J; Buttgereit F; Dunstan CR; Seibel MJ; Zhou H
Steroids; 2010 Mar; 75(3):282-6. PubMed ID: 20096296
[TBL] [Abstract][Full Text] [Related]
9. Osteoblast menin regulates bone mass in vivo.
Kanazawa I; Canaff L; Abi Rafeh J; Angrula A; Li J; Riddle RC; Boraschi-Diaz I; Komarova SV; Clemens TL; Murshed M; Hendy GN
J Biol Chem; 2015 Feb; 290(7):3910-24. PubMed ID: 25538250
[TBL] [Abstract][Full Text] [Related]
10. Activation of Nfatc2 in osteoblasts causes osteopenia.
Zanotti S; Canalis E
J Cell Physiol; 2015 Jul; 230(7):1689-95. PubMed ID: 25573264
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of H1 calponin in osteoblast lineage cells leads to a decrease in bone mass by disrupting osteoblast function and promoting osteoclast formation.
Su N; Chen M; Chen S; Li C; Xie Y; Zhu Y; Zhang Y; Zhao L; He Q; Du X; Chen D; Chen L
J Bone Miner Res; 2013 Mar; 28(3):660-71. PubMed ID: 23044709
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of the G-protein alpha-subunit G(s)alpha in osteoblasts leads to differential effects on trabecular and cortical bone.
Sakamoto A; Chen M; Nakamura T; Xie T; Karsenty G; Weinstein LS
J Biol Chem; 2005 Jun; 280(22):21369-75. PubMed ID: 15797856
[TBL] [Abstract][Full Text] [Related]
13. Transgenic overexpression of ephrin b1 in bone cells promotes bone formation and an anabolic response to mechanical loading in mice.
Cheng S; Kesavan C; Mohan S; Qin X; Alarcon CM; Wergedal J; Xing W
PLoS One; 2013; 8(7):e69051. PubMed ID: 23874863
[TBL] [Abstract][Full Text] [Related]
14. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation.
Bennett CN; Ouyang H; Ma YL; Zeng Q; Gerin I; Sousa KM; Lane TF; Krishnan V; Hankenson KD; MacDougald OA
J Bone Miner Res; 2007 Dec; 22(12):1924-32. PubMed ID: 17708715
[TBL] [Abstract][Full Text] [Related]
15. Lef1DeltaN binds beta-catenin and increases osteoblast activity and trabecular bone mass.
Hoeppner LH; Secreto FJ; Razidlo DF; Whitney TJ; Westendorf JJ
J Biol Chem; 2011 Apr; 286(13):10950-9. PubMed ID: 21270130
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.
O'Brien CA; Jia D; Plotkin LI; Bellido T; Powers CC; Stewart SA; Manolagas SC; Weinstein RS
Endocrinology; 2004 Apr; 145(4):1835-41. PubMed ID: 14691012
[TBL] [Abstract][Full Text] [Related]
17. Reduced trabecular bone mass and strength in mice overexpressing Gα11 protein in cells of the osteoblast lineage.
Dela Cruz A; Mattocks M; Sugamori KS; Grynpas MD; Mitchell J
Bone; 2014 Feb; 59():211-22. PubMed ID: 24308950
[TBL] [Abstract][Full Text] [Related]
18. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
19. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.
Mukherjee PM; Wang CJ; Chen IP; Jafarov T; Olsen BR; Ueki Y; Reichenberger EJ
Am J Orthod Dentofacial Orthop; 2010 Aug; 138(2):140.e1-140.e11; discussion 140-1. PubMed ID: 20691350
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes.
Shalhoub V; Conlon D; Tassinari M; Quinn C; Partridge N; Stein GS; Lian JB
J Cell Biochem; 1992 Dec; 50(4):425-40. PubMed ID: 1469073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
